These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

749 related articles for article (PubMed ID: 22642194)

  • 1. Matrix metalloproteinase inhibitors as investigative tools in the pathogenesis and management of vascular disease.
    Benjamin MM; Khalil RA
    Exp Suppl; 2012; 103():209-79. PubMed ID: 22642194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Matrix Metalloproteinase Inhibitors as Investigational and Therapeutic Tools in Unrestrained Tissue Remodeling and Pathological Disorders.
    Liu J; Khalil RA
    Prog Mol Biol Transl Sci; 2017; 148():355-420. PubMed ID: 28662828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease.
    Raffetto JD; Khalil RA
    Biochem Pharmacol; 2008 Jan; 75(2):346-59. PubMed ID: 17678629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Matrix metalloproteinases as potential targets in the venous dilation associated with varicose veins.
    Kucukguven A; Khalil RA
    Curr Drug Targets; 2013 Mar; 14(3):287-324. PubMed ID: 23316963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Matrix Metalloproteinases, Vascular Remodeling, and Vascular Disease.
    Wang X; Khalil RA
    Adv Pharmacol; 2018; 81():241-330. PubMed ID: 29310800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Matrix metalloproteinase inhibitors.
    Wojtowicz-Praga SM; Dickson RB; Hawkins MJ
    Invest New Drugs; 1997; 15(1):61-75. PubMed ID: 9195290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physiological Properties, Functions, and Trends in the Matrix Metalloproteinase Inhibitors in Inflammation-Mediated Human Diseases.
    Kim IS; Yang WS; Kim CH
    Curr Med Chem; 2023; 30(18):2075-2112. PubMed ID: 36017851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation and involvement of matrix metalloproteinases in vascular diseases.
    Amin M; Pushpakumar S; Muradashvili N; Kundu S; Tyagi SC; Sen U
    Front Biosci (Landmark Ed); 2016 Jan; 21(1):89-118. PubMed ID: 26709763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biochemical and Biological Attributes of Matrix Metalloproteinases.
    Cui N; Hu M; Khalil RA
    Prog Mol Biol Transl Sci; 2017; 147():1-73. PubMed ID: 28413025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Matrix metalloproteinases (MMPs) in health and disease: an overview.
    Malemud CJ
    Front Biosci; 2006 May; 11():1696-701. PubMed ID: 16368548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Matrix Metalloproteinases Inhibitors in Cancer Treatment: An Updated Review (2013-2023).
    Almutairi S; Kalloush HM; Manoon NA; Bardaweel SK
    Molecules; 2023 Jul; 28(14):. PubMed ID: 37513440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Matrix Metalloproteinases as Regulators of Vein Structure and Function: Implications in Chronic Venous Disease.
    MacColl E; Khalil RA
    J Pharmacol Exp Ther; 2015 Dec; 355(3):410-28. PubMed ID: 26319699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Next generation matrix metalloproteinase inhibitors - Novel strategies bring new prospects.
    Levin M; Udi Y; Solomonov I; Sagi I
    Biochim Biophys Acta Mol Cell Res; 2017 Nov; 1864(11 Pt A):1927-1939. PubMed ID: 28636874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Matrix Metalloproteinases in Remodeling of Lower Extremity Veins and Chronic Venous Disease.
    Chen Y; Peng W; Raffetto JD; Khalil RA
    Prog Mol Biol Transl Sci; 2017; 147():267-299. PubMed ID: 28413031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metalloproteinase inhibition ameliorates hypertension and prevents vascular dysfunction and remodeling in renovascular hypertensive rats.
    Castro MM; Rizzi E; Figueiredo-Lopes L; Fernandes K; Bendhack LM; Pitol DL; Gerlach RF; Tanus-Santos JE
    Atherosclerosis; 2008 Jun; 198(2):320-31. PubMed ID: 18054360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Matrix metalloproteinases (MMPs), the main extracellular matrix (ECM) enzymes in collagen degradation, as a target for anticancer drugs.
    Jabłońska-Trypuć A; Matejczyk M; Rosochacki S
    J Enzyme Inhib Med Chem; 2016; 31(sup1):177-183. PubMed ID: 27028474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Matrix metalloproteinases: targets for doxycycline to prevent the vascular alterations of hypertension.
    Castro MM; Tanus-Santos JE; Gerlach RF
    Pharmacol Res; 2011 Dec; 64(6):567-72. PubMed ID: 21514386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spatiotemporal expression patterns of metalloproteinases and their inhibitors in the postnatal developing rat cerebellum.
    Vaillant C; Didier-Bazès M; Hutter A; Belin MF; Thomasset N
    J Neurosci; 1999 Jun; 19(12):4994-5004. PubMed ID: 10366632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Roles of Matrix Metalloproteinases and Their Natural Inhibitors in Metabolism: Insights into Health and Disease.
    Molière S; Jaulin A; Tomasetto CL; Dali-Youcef N
    Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The role of metalloproteinases in modification of extracellular matrix in invasive tumor growth, metastasis and angiogenesis].
    Fink K; Boratyński J
    Postepy Hig Med Dosw (Online); 2012 Sep; 66():609-28. PubMed ID: 23001203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.